Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
AI drug discovery platform developing novel biologics for cancer and AMR
AMPLY Discovery is a biotechnology company developing an AI-driven drug discovery platform that combines machine learning, next-generation sequencing, and synthetic biology to identify novel biologic drug candidates from natural biological diversity. The platform digitises biological molecules, identifies treatment…
Synthetic glycan-targeted small molecules for next-generation immunotherapy
Anomer Bio is a biotechnology company developing synthetic monosaccharides and small molecule drugs that target glycans, the sugars coating cell surfaces that influence immune responses and disease. Its platform combines multi-omics data and machine learning to model how cells process sugars, enabling the design of…
Precision therapeutics targeting fibrosis using multi-omics
Forth Therapeutics develops precision medicines intended to target the cellular mechanisms driving organ fibrosis. Its discovery platform combines single-cell and spatial genomics with patient-derived tissue data, including a large human liver disease dataset. These insights help identify disease-associated cells and…
Small molecule therapeutics targeting PDE4 enzymes in kidney disease
Mironid is a company developing first-in-class small molecule therapeutics for autosomal dominant polycystic kidney disease, one of the most common hereditary kidney disorders. Its lead programme targets long-form PDE4 enzymes to modulate cyclic AMP signalling, the central driver of cyst growth across all disease…
Organ-specific liquid biopsy tests for early cancer detection
Mursla Bio is a diagnostics company developing blood-based tests for early cancer detection using extracellular vesicle biology. Its platform isolates organ-specific extracellular vesicles from blood and applies multi-omics profiling and machine learning to identify disease biomarkers without tissue biopsy. Its lead…
Targeted oral drug delivery platform for cancer, CNS and respiratory disease
TRX Biosciences is a biotechnology company developing a targeted oral drug delivery platform, enabling therapies to reach specific organs, cells and tissues for cancer, central nervous system, respiratory and immune system diseases. The company's technology is licensed to partner companies for use in their own drug…
RNA-targeted drug discovery platform using machine learning
RevoNA Bio is a biotechnology company developing a high-throughput RNA biological platform for RNA-targeted drug discovery. The platform generates comprehensive RNA structural and functional datasets that feed a machine learning predictive engine, supporting hit identification, structure-activity relationship…
Targeted therapies against extrachromosomal DNA in cancer
Econic Biosciences is a drug discovery biotech developing therapies that target extrachromosomal DNA, a circular form of DNA found outside normal chromosomes that drives oncogene amplification, tumour evolution, and treatment resistance across multiple cancer types. The company uses AI to identify and characterise…
PET radiopharmaceutical diagnostics for cancer imaging
Blue Earth Diagnostics Limited is a molecular imaging company developing and commercialising PET radiopharmaceuticals for cancer diagnosis and treatment planning. The company serves clinicians, healthcare systems and patients by providing administered imaging agents that support clinical decision making in oncology.…
AI-designed extended-expression RNA therapeutics for cardio-metabolic disease
ScionxBio, formerly Eleven Therapeutics, is a biotechnology company developing xRNA, a chemically expanded RNA modality engineered to extend protein expression from days to months. Combinatorial chemistry and deep learning are combined to design molecules with enhanced stability and reduced immune sensing, enabling…
Small molecule neuromodulators for neuropsychiatric disorders
Draig Therapeutics is a clinical-stage biotech developing small molecule drugs that modulate the glutamate and GABA neurotransmitter pathways to treat neuropsychiatric disorders. Its lead candidate DT-101 is an AMPA receptor positive allosteric modulator in Phase 2 development for major depressive disorder. The…
Small-molecule drugs targeting cellular ageing and senescence
Five Alarm Bio Limited is a biotechnology company discovering small-molecule therapies for diseases associated with ageing. Its research targets chemical damage that accumulates inside cells, aiming to reinforce protective mechanisms and delay cellular senescence rather than destroy senescent cells. Candidate…
Biotech venture builder co-creating and scaling drug discovery companies
Molecule to Medicine (MTM) is a biotech venture builder that co-creates, builds, and scales drug discovery companies within a shared operational ecosystem, combining drug discovery expertise with shared infrastructure to enable rapid company formation. UK operations are based at Milton Park, Abingdon, with a further…
Multiomics platform for cancer biomarker discovery and diagnostics
Tagomics is a Cambridge-based biotech developing a multiomics platform for disease biomarker discovery and diagnostics. Its platform integrates genomics, epigenomics and fragmentomics with advanced bioinformatics and machine learning to identify disease-associated DNA markers from blood and other biological sources.…
Fragment and structure-based drug discovery services
Vernalis (R&D) is a Cambridge-based contract drug discovery organisation specialising in fragment-based and structure-based drug discovery. The company integrates structural biology, biophysics, NMR spectroscopy, DNA-encoded library screening, medicinal chemistry, and computational approaches to identify and progress…
CASPAROV AI platform for targets in heterogeneous cancers
Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance. Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent…
AI platform targeting chromosomal instability across cancer
Tailor Bio is a Cambridge-based biotechnology company developing an AI-driven precision medicine platform for cancers with chromosomal instability, a genomic phenomenon present in over 80% of all cancers. Founded from research originating at the Cancer Research UK Cambridge Institute, the company develops both…
E3 ligase inhibitors stabilising tumour suppressor proteins
Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune…
RNA-based therapeutics targeting neurodegenerative disease mechanisms
Harness Therapeutics is a Cambridge-based biotech developing oligonucleotide therapeutics that exploit post-transcriptional regulation to achieve controlled upregulation of disease-relevant proteins in the CNS. Its lead programme targets FAN1 nuclease in Huntington's disease to limit somatic DNA repeat expansion, with…
Nanotechnology-based point-of-care cardiovascular diagnostics for decentralised healthcare
The NanoBioTechnology Hub is a Manchester-based developer of miniaturised point-of-care diagnostic devices using nanotechnology and biotechnology. The company is developing an ultra-sensitive handheld device for pre-hospital cardiovascular biomarker analysis, using lateral flow technology and biointerfaced…